Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00270

Target Information
NameMast/stem cell growth factor receptor    
Type of targetSuccessful target    
CD117 antigen    
Proto-oncogene tyrosine-protein kinase Kit    
DiseaseCancer, unspecific
[ICD9: 140-229   ICD10: C00-C96]
Gastrointestinal stromal tumors
[ICD9: 150-159   ICD10: C15-C26]
Malignant phyllodes tumours
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Ovarian cancer
[ICD9: 183   ICD10: C56]
Phyllodes tumours
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Renal cell carcinoma
[ICD9: 189   ICD10: C64]
Small cell lung cancer
[ICD9: 162.9   ICD10: C34.90]
Drug(s)Pazopanib HClApprovedRenal cell carcinoma[8]
PonatinibApprovedChronic, accelerated or blast-phase chronic myeloid leukaemia
RegorafenibApprovedMetastatic colorectal cancer
ImatinibLaunchedChronic myelogenous leukemia [9]
SunitinibLaunchedAdvanced renal cell carcinoma[10][11][9][12]
Sunitinib malatePhase IVMetastatic Renal Cell Carcinoma; Gastrointestinal Stromal Tumors[13][14][9]
ImatinibPhase IIIIntestinal cancer & myeloid leukemia[9]
MotesanibPhase IIINon-small cell lung cancer[15][16][17]
NilotinibPhase IIILeukemia[9]
PazopanibPhase IIIAdvanced / metastatic renal cancer[9][18][19]
PazopanibPhase II completedSolid tumours, NSCLC[9][18][19]
ImatinibPhase IIGlioma, lung, prostate, solid tumours[9]
MotesanibPhase IIBreast cancer[15][16][17]
NilotinibPhase IIALL, CML, GIST[9]
PLX3397Phase IIAcute myeloid leukemia
PLX3397Phase IIGlioblastoma
PLX3397Phase IIGlioblastoma (GBM)
PLX3397Phase IIHodgkin lymphoma
PLX3397Phase IIMetastatic Breast cancer
PLX3397Phase IIMetastatic Prostate cancer
PLX3397Phase IIProstate Caner
SunitinibPhase IIAdvanced renal cell carcinoma[10][11][9][12]
Sunitinib malatePhase IISoft Tissue Sarcoma[13][14][9]
PLX3397Phase I/IIAcute myelogenous lymphoma (AML)
MP470Phase ISolid Tumors[20]
Motesanib diphosphatePhase IProgressive non-small cell lung cancer[21][16]
OSI-930Phase IVarious cancers[9]
BioChemical ClassTransferases transferring phosphorus-containing groups    
EC NumberEC
PathwayAcute myeloid leukemia
Cytokine-cytokine receptor interaction
Hematopoietic cell lineage
Pathways in cancer
UniProt IDP10721
PDB Structure1PKG; 1QZJ; 1QZK; 1R01; 1T45; 1T46; 2E9W; 2EC8; 2VIF; 3G0E; 3G0F; 4HVS.    
FunctionThis is the receptor for stem cell factor (mast cell growth factor). It has a tyrosine-protein kinase activity. binding of the ligands leads to the autophosphorylation of kit and its association with substrates such as phosphatidylinositol 3-kinase (pi3k).    
Related US Patent6,642,232
Target ValidationClick to Find Target Validation Information.    
Inhibitor4- (4-aminophenyl)-1H-indazol-3yl-amine[22]
Bis- (5-hydroxy-1H-indol-2-yl)-methanone[26]
Motesanib diphosphate[21][16]
PD-0166326,   PD-166326[27]
Pazopanib HCl[8]
Sunitinib malate[13][14][9]
Motesanib diphosphate[21][16]
Pazopanib HCl[8]
Sunitinib malate[13][14][9]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003 Sep 29;22(42):6589-97. To Reference
Ref 2Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. Epub 2003 Sep 9. To Reference
Ref 3KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15;61(22):8118-21. To Reference
Ref 4CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol. 2003 Jun;14(6):894-7. To Reference
Ref 5KIT in ovarian carcinoma: disillusion about a potential therapeutic target. J Natl Cancer Inst. 2003 Jul 2;95(13):1009-10. To Reference
Ref 6Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol. 2003 May;200(1):59-64. To Reference
Ref 7Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003 Feb 13;22(6):847-52. To Reference
Ref 8Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. To Reference
Ref 9A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 10FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun;12(3):81-9. Epub 2009 May 20. To Reference
Ref 11FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41. Epub 2009 Mar 24. To Reference
Ref 12Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference
Ref 13Pfizer. Product Development Pipeline. March 31 2009. To Reference
Ref 14Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. Epub 2008 Oct 29. To Reference
Ref 15Amgen. Product Development Pipeline. February 6 2009. To Reference
Ref 16Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10;27(23):3794-801. Epub 2009 Jun 29. To Reference
Ref 17Amgen. Report of Amgen. 2009. To Reference
Ref 18GSK. Product Development Pipeline. February 2009. To Reference
Ref 19Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35. To Reference
Ref 20MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142. To Reference
Ref 21Takeda. Product Development Pipeline. July 31 2009. To Reference
Ref 22J Med Chem. 2007 Apr 5;50(7):1584-97. Epub 2007 Mar 8.Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. To Reference
Ref 23J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. To Reference
Ref 24J Med Chem. 2006 Nov 2;49(22):6465-88.N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. To Reference
Ref 25Nucleic Acids Res. 2011 January; 39(Database issue): D1035¨CD1041. DrugBank 3.0: a comprehensive resource for ¡®Omics¡¯ research on drugs To Reference
Ref 26J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. To Reference
Ref 27Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. Epub 2009 Oct 23.Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. To Reference
Ref 28Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 29J Med Chem. 2000 Jun 15;43(12):2310-23.New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543